Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study counts how many preemies get eylea for blinding eye condition

NCT ID NCT06315556

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 31 times

Summary

This study looks at how often preterm babies with retinopathy of prematurity (ROP) receive the medicine Eylea using a special pediatric dosing device in the UK. Researchers will collect data from a national database on up to 200 babies born between 2024 and 2026. The goal is to see if enough babies are treated to later study the long-term safety of this treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRETERM INFANTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Many locations

    RECRUITING

    Multiple Locations, United Kingdom

Conditions

Explore the condition pages connected to this study.